

Matthias I. Gröschel

as of August 2023

Department of Infectious Diseases and Pulmonary Medicine
 Charité – Universitätsmedizin Berlin
 Charitéplatz 1, 10117 Berlin, Germany

Matthias.groeschel@charite.de
mgro.github.io

Education

Ph.D. Infectious Disease Genomics. University of Groningen, The Netherlands, 2019
 (2015-2016 at Institut Pasteur, Paris, 2017-2019 at Research Center Borstel, Borstel)

M.D. University of Groningen, The Netherlands, 2017

B.S. International Medicine / Global Health . University of Groningen, The Netherlands, 2013

B.A. Philosophy. University of Groningen, The Netherlands, 2013

Employment

Resident Physician Internal Medicine, Charité – Universitätsmedizin Berlin, 2022 – present

Junior Digital Clinician Scientist, Berlin Institute of Health, 2022 – present

Research fellow at Harvard Medical School, 2019 – present

Junior Professional Officer, International Communication Union, 2021 – 2022

Consultant, World Health Organization Regional Office for Europe, 2018 – 2020

Papers and preprints

Selected Original and Reviews (for full list see [google scholar](#) or [pubmed](#))

- 2023 Farlow A, Hoffmann A, Tadesse GA, Mzurikwao D, Beyer R, Akogo D, Weicken E, Matika T, Nweje MI, Wamae W, Arts S, Wiegand T, Bennett C, Farhat MR, **Groschel MI**. Rethinking global digital health and AI-for-health innovation challenges. *PLOS Glob Public Health*. 2023;28(3):e0001844
- 2022 **Groschel MI**, van den Boom M, Dixit A, Skrahina A, Dodd PJ, Migliori GB, Seddon JA, Farhat MR. Management of childhood MDR-TB in Europe and Central Asia. *Int J Tuberc Lung Dis* 2022; 26(5):433-440
- 2021 **Groschel MI**, Owens M, Freschi L, Vargas Jr R, Marin MG, Phelan J, Iqbal Z, Dixit A, Farhat MR. GenTB: A user-friendly genome-based predictor for tuberculosis resistance powered by machine learning. *Genome Med* 2021; 13, 138
- 2021 **Groschel MI** and Farhat MR. A legacy of disease. *Lancet Inf Dis* 2021; 10.1016/S1473-3099(21)00165-1
- 2020 Rankin NA, **Groschel MI**, Farhat MR. Mentorship at a distance. *Science* 2020; 370(6515):494

Groschel MI et al. The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist *Stenotrophomonas maltophilia*, Nature Communications 2020; 10:1038/s41467-020-15123-0

2019 **Groschel MI**, Seddon JA, Prabowo SA, Migliori GB, Graham SM, van den Boom M, Dara M. European Guidance on drug-resistant tuberculosis in children and adolescents. Lancet Child & Adolesc Health 2019;10:1016/S2352-4642(19)30332-3.

Lead writing and coordination of WHO guidance: Multidrug-resistant tuberculosis in children and adolescents in the WHO European Region, Expert Opinion. Copenhagen: WHO Regional Office for Europe; 2019.

Groschel MI, van den Boom M, Migliori GB, Dara M. Prioritising children and adolescents in the tuberculosis response of the WHO European Region. Eur Respir Rev 2019;10:1183/16000617.0106-2018.

Groschel MI, Luz CF, Batra S, Ahuja S, Batra S, Kranzer K, van der Werf TS. Random glucose sampling as screening tool for diabetes among disadvantaged tuberculosis patients residing in urban slums in India. ERJ Open Research 2019; 5:00025-2019

2018 Soenke A*, **Groschel MI***, Hillemann D, Niemann S, Merker M, Kranzer K. A diagnostic algorithm to investigate pyrazinamide and ethambutol resistance in rifampicin resistant *Mycobacterium tuberculosis* isolates in a low incidence setting. Antimicrobial Agents Chemotherapy 2018; DOI: 10.1128/AAC.01798-18

Groschel MI, Walker T, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for multidrug-resistant tuberculosis. PloS Pathog 2018;14(10):e1007297

2017 **Groschel MI**, Sayes F, ..., Brosch R. Recombinant BCG expressing ESX-1 of *Mycobacterium marinum* combines low virulence with cytosolic immune signalling and improved tuberculosis protection. Cell Reports 2017;18:2752-2765

2016 **Groschel MI**, Sayes F, Roxane S, Majlessi L, Brosch R. ESX secretion systems: mycobacterial evolution to counter host immunity. Nat Rev Microbiol 2016 Nov;14(11):677-691

Lai FY, **Groschel MI**, van den Hende L, Diercks, GF, Rutgers A, van der Werf TS. Prolonged pyrexia and subtle skin lesions: polyarteritis nodosa. Lancet 2016;5(387):1025-6.

Groschel MI, Omansen TF, de Lange W, van der Werf TS, Lokate M, Bathoorn E, Akkerman OW, Stienstra Y. Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae. Am J Trop Med Hyg 2016;94(3):517-8.

2015 **Groschel MI**, Prabowo SA, Cardona PJ, Stanford JL, van der Werf TS. Therapeutic Vaccines for Tuberculosis – a Systematic Review. Vaccine 2014;32(26):3162-8.

Awards

- 2020 **Annual PhD Price**, Paul Ehrlich Society
- 2019 **Annual PhD Price**, Research Center Borstel and Municipality of Bad Segeberg
- 2018 **Annual Research Price**, Hippocrates Foundation, Leiden, Netherlands
- 2017 **Best Translational Poster**, Innate Immunity Symposium Freiburg, Germany
- 2014 **Best M.sc. Thesis of the year**, Alumni Association Faculty of Medicine, University of Groningen